Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis

Lynn Soong, S. M. Duboise, P. Kima, D. McMahon-Pratt

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

In the search for a leishmaniasis vaccine, extensive studies have been carried out with promastigote (insect stage) molecules. Information in this regard on amastigote (mammalian host stage) molecules is limited. To investigate host immune responses to Leishmania amastigote antigens, we purified three stage-specific antigens (A2, P4, and P8) from in vitro- cultivated amastigotes of Leishmania pifanoi by using immunoaffinity chromatography. We found that with Corynebacterium parvum as an adjuvant, three intraperitoneal injections of 5 μg of P4 or P8 antigen provided partial tn complete protection of BALB/c mice challenged with 105 to 107 L. pifanoi promastigotes. These immunized mice developed significantly smaller or no lesions and exhibited a 39- to 1.6 x 105-fold reduction of lesion parasite burden after 15 to 20 weeks of infection. In addition, P8 immunization resulted in complete protection against L. amazonensis infection of CBA/J mice and partial protection of BALB/c mice, suggesting that this antigen provided cross-species protection of mice with different H-2 haplotypes. At different stages during infection, vaccinated mice exhibited profound proliferative responses to parasite antigens and increased levels of gamma interferon production, suggesting that a Th1 cell-mediated immune response is associated with the resistance in these mice. Taken together, the data in this report indicate the vaccine potential of amastigote-derived antigens.

Original languageEnglish (US)
Pages (from-to)3559-3566
Number of pages8
JournalInfection and Immunity
Volume63
Issue number9
StatePublished - 1995
Externally publishedYes

Fingerprint

Cutaneous Leishmaniasis
Leishmania
Antigens
Leishmaniasis Vaccines
Parasites
Infection
Cross Protection
Propionibacterium acnes
Inbred CBA Mouse
Th1 Cells
Intraperitoneal Injections
varespladib methyl
Haplotypes
Interferon-gamma
Insects
Chromatography
Immunization
Vaccines

ASJC Scopus subject areas

  • Immunology

Cite this

Soong, L., Duboise, S. M., Kima, P., & McMahon-Pratt, D. (1995). Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infection and Immunity, 63(9), 3559-3566.

Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. / Soong, Lynn; Duboise, S. M.; Kima, P.; McMahon-Pratt, D.

In: Infection and Immunity, Vol. 63, No. 9, 1995, p. 3559-3566.

Research output: Contribution to journalArticle

Soong, L, Duboise, SM, Kima, P & McMahon-Pratt, D 1995, 'Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis', Infection and Immunity, vol. 63, no. 9, pp. 3559-3566.
Soong, Lynn ; Duboise, S. M. ; Kima, P. ; McMahon-Pratt, D. / Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. In: Infection and Immunity. 1995 ; Vol. 63, No. 9. pp. 3559-3566.
@article{8d7569ea89b848dd9368996d2f84a8fa,
title = "Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis",
abstract = "In the search for a leishmaniasis vaccine, extensive studies have been carried out with promastigote (insect stage) molecules. Information in this regard on amastigote (mammalian host stage) molecules is limited. To investigate host immune responses to Leishmania amastigote antigens, we purified three stage-specific antigens (A2, P4, and P8) from in vitro- cultivated amastigotes of Leishmania pifanoi by using immunoaffinity chromatography. We found that with Corynebacterium parvum as an adjuvant, three intraperitoneal injections of 5 μg of P4 or P8 antigen provided partial tn complete protection of BALB/c mice challenged with 105 to 107 L. pifanoi promastigotes. These immunized mice developed significantly smaller or no lesions and exhibited a 39- to 1.6 x 105-fold reduction of lesion parasite burden after 15 to 20 weeks of infection. In addition, P8 immunization resulted in complete protection against L. amazonensis infection of CBA/J mice and partial protection of BALB/c mice, suggesting that this antigen provided cross-species protection of mice with different H-2 haplotypes. At different stages during infection, vaccinated mice exhibited profound proliferative responses to parasite antigens and increased levels of gamma interferon production, suggesting that a Th1 cell-mediated immune response is associated with the resistance in these mice. Taken together, the data in this report indicate the vaccine potential of amastigote-derived antigens.",
author = "Lynn Soong and Duboise, {S. M.} and P. Kima and D. McMahon-Pratt",
year = "1995",
language = "English (US)",
volume = "63",
pages = "3559--3566",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis

AU - Soong, Lynn

AU - Duboise, S. M.

AU - Kima, P.

AU - McMahon-Pratt, D.

PY - 1995

Y1 - 1995

N2 - In the search for a leishmaniasis vaccine, extensive studies have been carried out with promastigote (insect stage) molecules. Information in this regard on amastigote (mammalian host stage) molecules is limited. To investigate host immune responses to Leishmania amastigote antigens, we purified three stage-specific antigens (A2, P4, and P8) from in vitro- cultivated amastigotes of Leishmania pifanoi by using immunoaffinity chromatography. We found that with Corynebacterium parvum as an adjuvant, three intraperitoneal injections of 5 μg of P4 or P8 antigen provided partial tn complete protection of BALB/c mice challenged with 105 to 107 L. pifanoi promastigotes. These immunized mice developed significantly smaller or no lesions and exhibited a 39- to 1.6 x 105-fold reduction of lesion parasite burden after 15 to 20 weeks of infection. In addition, P8 immunization resulted in complete protection against L. amazonensis infection of CBA/J mice and partial protection of BALB/c mice, suggesting that this antigen provided cross-species protection of mice with different H-2 haplotypes. At different stages during infection, vaccinated mice exhibited profound proliferative responses to parasite antigens and increased levels of gamma interferon production, suggesting that a Th1 cell-mediated immune response is associated with the resistance in these mice. Taken together, the data in this report indicate the vaccine potential of amastigote-derived antigens.

AB - In the search for a leishmaniasis vaccine, extensive studies have been carried out with promastigote (insect stage) molecules. Information in this regard on amastigote (mammalian host stage) molecules is limited. To investigate host immune responses to Leishmania amastigote antigens, we purified three stage-specific antigens (A2, P4, and P8) from in vitro- cultivated amastigotes of Leishmania pifanoi by using immunoaffinity chromatography. We found that with Corynebacterium parvum as an adjuvant, three intraperitoneal injections of 5 μg of P4 or P8 antigen provided partial tn complete protection of BALB/c mice challenged with 105 to 107 L. pifanoi promastigotes. These immunized mice developed significantly smaller or no lesions and exhibited a 39- to 1.6 x 105-fold reduction of lesion parasite burden after 15 to 20 weeks of infection. In addition, P8 immunization resulted in complete protection against L. amazonensis infection of CBA/J mice and partial protection of BALB/c mice, suggesting that this antigen provided cross-species protection of mice with different H-2 haplotypes. At different stages during infection, vaccinated mice exhibited profound proliferative responses to parasite antigens and increased levels of gamma interferon production, suggesting that a Th1 cell-mediated immune response is associated with the resistance in these mice. Taken together, the data in this report indicate the vaccine potential of amastigote-derived antigens.

UR - http://www.scopus.com/inward/record.url?scp=0029120131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029120131&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 3559

EP - 3566

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 9

ER -